PRESS RELEASE - PRIVILEGED INFORMATION In view of the restructuring plan announced on April 11, 2024, BioSenic has decided to postpone the publication of its 2023 annual report as well as its...
PRESS RELEASE “ REGULATED INFORMATION Article 14 of the Law of 2 May 2007 on disclosure of major holdings Mont-Saint-Guibert, Belgium, April 18, 2024, 7am CET “ BIOSENIC (Euronext...
PRESS RELEASE - PRIVILEGED INFORMATION Mont-Saint-Guibert, Belgium, 12 April 2024, 12:00 CET €“ BioSenic (Euronext Brussels and Paris: BIOS), the clinical-stage company specializing in serious...
PRESS RELEASE - PRIVILEGED INFORMATION A final circular of the creditors on the basis of XX 83/23 of the Economic Law Code (ELC) will take place before the Court grants authorisation, in accordance...
PRESS RELEASE “ REGULATED INFORMATION Mont-Saint-Guibert, Belgium, March 29, 2024, 7.00 am CEST “ BIOSENIC (Euronext Brussels and Paris: BIOS), the clinical-stage company specializing in serious...
PRESS RELEASE Preclinical data in a transgenic mouse model shows beneficial effects on various clinical symptoms analogous to those observed in human systemic sclerosis.Findings may further support...
BioSenic releases details of optimized administration approach
BioSenic S.A. : Information on the total number of voting rights and shares
BioSenic raises ‚¬500,000 in private placement of new shares
Mont-Saint-Guibert, Belgium, January 31, 2024, 7.00 am CEST “ BioSenic (Euronext Brussels and Paris: BIOS), the clinical-stage company specializing in serious autoimmune and inflammatory diseases and...